Equivalent to 40000ui of epo alpha by customers report
third-generation molecule, Continuous Erythropoietin Receptor Activator (CERA), incorporating a large polymer chain, has been developed. CERA has an elimination half-life that is considerably longer than the half-life of either epoetin or darbepoetin alfa. CERA may also have different receptor binding characteristics and pharmacology from other erythropoietic agents; CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This offers a potential advantage over other erythropoietin-stimulating agents that require more frequent administration. Studies involving erythropoietin-naïve patients found no difference between correcting renal anemia with CERA once every two weeks compared to results with other erythropoietin-stimulating agents that were administered up to three times weekly. Compared to previous erythropoietin-stimulating agents, CERA has a dramatically lengthened half-life, making it the only erythropoietin-stimulating agents licensed for once-a-month dosing.